Piramal Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of Rs. 0.14 per equity share.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.0 pts less than Nifty Smallcap 250 and 5.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Piramal Pharma's board, meeting on May 14, 2025, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone revenue from operations grew to Rs. 5,285.71 crore (up from Rs. 4,390.11 crore in FY24) and net profit rose sharply to Rs. 691.40 crore (from Rs. 391.22 crore), with EPS at Rs. 5.22. Consolidated revenue stood at Rs. 9,151.18 crore with net profit of Rs. 91.13 crore (vs Rs. 17.82 crore). The board recommended a final dividend of Rs. 0.14 per equity share (face value Rs. 10), subject to shareholder approval. Mr. Neeraj Bharadwaj (Carlyle nominee) resigned as a non-executive, non-independent director, replaced by Mr. Amit Jain (also a Carlyle nominee). Mr. Jairaj Purandare was re-appointed as an independent director for a second 5-year term effective February 9, 2026.
Strong standalone profit growth of around 77% year-on-year and improved consolidated earnings are positive signals for shareholders. The final dividend of Rs. 0.14 per share is modest and is unlikely to materially affect stock price, while the Carlyle-nominee director change is a routine board reshuffle and not a material event for investors.